Integragen
ALINT
Company Profile
Business description
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
Contact
Genopole Campus 1 - Genavenir
85 rue Henri Desbrueres
Evry91000
FRAT: +33 160910900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
39
Stocks News & Analysis
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.00 | 21.50 | -0.24% |
| CAC 40 | 8,230.49 | 6.94 | -0.08% |
| DAX 40 | 25,078.16 | 185.96 | 0.75% |
| Dow JONES (US) | 49,292.62 | 169.46 | -0.34% |
| FTSE 100 | 10,043.02 | 79.71 | -0.79% |
| HKSE | 26,458.95 | 251.50 | -0.94% |
| NASDAQ | 23,602.91 | 55.73 | 0.24% |
| Nikkei 225 | 51,961.98 | 556.10 | -1.06% |
| NZX 50 Index | 13,715.02 | 51.44 | 0.38% |
| S&P 500 | 6,945.82 | 1.00 | 0.01% |
| S&P/ASX 200 | 8,695.60 | 27.90 | -0.32% |
| SSE Composite Index | 4,085.77 | 2.10 | 0.05% |